+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment with exogenous surfactant stimulates endogenous surfactant synthesis in premature infants with respiratory distress syndrome



Treatment with exogenous surfactant stimulates endogenous surfactant synthesis in premature infants with respiratory distress syndrome



Critical Care Medicine 28(10): 3383-3388



Treatment of preterm infants with respiratory distress syndrome (RDS) with exogenous surfactant has greatly improved clinical outcome. Some infants require multiple doses, and it has not been studied whether these large amounts of exogenous surfactant disturb endogenous surfactant metabolism in humans. We studied endogenous surfactant metabolism in relation to different amounts of exogenous surfactant, administered as rescue therapy for RDS. Prospective clinical study. Neonatal intensive care unit in a university hospital. A total of 27 preterm infants intubated and mechanically ventilated for respiratory insufficiency. Infants received a 24-hr infusion with the stable isotope [U-13C]glucose starting 5.3 +/- 0.5 hrs after birth. The 13C-incorporation into palmitic acid in surfactant phosphatidylcholine (PC) isolated from serial tracheal aspirates was measured. Infants received either zero (n = 5), one (n = 4), two (n = 15), or three (n = 3) doses of Survanta (100 mg/kg) when clinically indicated. Using multiple regression analysis, the absolute synthesis rate (ASR) of surfactant PC from plasma glucose increased with 1.3 +/- 0.4 mg/kg/day per dose of Survanta (p = .007) (mean +/- SEM). The ASR of surfactant PC from glucose was increased by prenatal corticosteroid treatment with 1.3 +/- 0.4 mg/kg/day per dose corticosteroid (p = .004), and by the presence of a patent ductus arteriosus with 2.1 +/- 0.7 mg/ kg/day (p = .01). These data are reassuring and show for the first time in preterm infants that multiple doses of exogenous surfactant for RDS are tolerated well by the developing lung and stimulate endogenous surfactant synthesis.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047839306

Download citation: RISBibTeXText

PMID: 11057790

DOI: 10.1097/00003246-200010000-00001


Related references

Exogenous surfactant for treatment of respiratory distress syndrome in premature infants. Journal of the Formosan Medical Association 89(2): 110-114, 1990

Incidence of bronchopulmonary dysplasia in premature infants with respiratory distress syndrome not receiving exogenous surfactant treatment. Pediatric Research 35(4 Part 2): 285A, 1994

Surfactant proteins and anti-surfactant antibodies in sera from infants with respiratory distress syndrome with and without surfactant treatment. Pediatrics 88(1): 84-89, 1991

A comparison of efficacy between two natural exogenous surfactant preparations in premature infants with respiratory distress syndrome. Klinische Padiatrie 216(4): 230-235, 2004

Surfactant proteins and stable microbubbles in tracheal aspirates of infants with respiratory distress syndrome: Relation to the degree of respiratory failure and response to exogenous surfactant. European Journal of Pediatrics 156(2): 131-138, 1997

Effect of exogenous surfactant therapy on levels of pulmonary surfactant proteins A and D in preterm infants with respiratory distress syndrome. Journal of Perinatal Medicine 37(5): 561-564, 2009

Pulmonary mechanics in ventilated preterm infants with respiratory distress syndrome after exogenous surfactant administration: a comparison between two surfactant preparations. Pediatric Pulmonology 18(5): 273-278, 1994

Modifications of surfactant phospholipid pattern splp in premature infants with respiratory distress syndrome rds receiving porcine surfactant replacement therapy. Pediatric Research 29(4 Part 2): 319A, 1991

Endogenous pulmonary surfactant metabolism is not affected by mode of ventilation in premature infants with respiratory distress syndrome. Journal of Pediatrics 140(6): 693-698, 2002

Surfactant treatment of premature infants with respiratory distress syndrome. Tidsskrift for den Norske Laegeforening 111(8): 1032-1033, 1991

Treatment of respiratory distress syndrome in premature infants with pulmonary surfactant. Klinische Padiatrie 201(6): 417-424, 1989

Surfactant treatment in premature infants with Respiratory Distress Syndrome in Curaçao. West Indian Medical Journal 50(2): 117-122, 2001

Surfactant protein A, phosphatidylcholine, and surfactant inhibitors in epithelial lining fluid. Correlation with surface activity, severity of respiratory distress syndrome, and outcome in small premature infants. American Review of Respiratory Disease 144(6): 1376-1384, 1991

Treatment of respiratory distress syndrome in very small premature infants with bovine surfactant. Monatsschrift Kinderheilkunde 138(1): 8, 1990

Acute effects of exogenous surfactant treatment in near-term infants with respiratory distress syndrome. Journal of Investigative Medicine 43(Suppl. 3): 463A, 1995